VÉRONIQUE DARTOIS, Ph



Véronique Dartois, Ph.D.

44 Union St #12 Telephone: +1 973 854 3160

Montclair, NJ 07042 Mobile: +1 646 589 2479

E-mail: veronique.dartois@rutgers.edu

PROFESSIONAL POSITIONS

2012–present Associate Professor, Public Health Research Institute, NJ Medical School, Rutgers, The State University of New Jersey

2005-2012 Executive Director, Pharmacology, Novartis Institute for Tropical Diseases, Singapore

• Established fully operational Pharmacology department in 2005, responsible for managing the department, including objective setting, performance management, prioritization, resource allocation and annual budget

• Managed a team of Research Associates, Post-doc Fellows and Principal Scientists to carry out in vitro and in vivo PK and efficacy studies supporting hit-to-lead, lead optimization and preclinical stages of drug discovery programs in Tuberculosis, Dengue fever and Malaria

• Coordinated internal and outsourced activities to provide allometric scaling, PK/PD analysis and modelling support to propose doses and dose ranges for efficacy studies and early drug development

• Contributed to the discovery and development of antimalarial clinical candidate NITD-609

• Managed research activities, including establishment of internal and external collaborations in the field of clinical PK studies, tissue distribution in animal models, and biomarker identification

• Director of Novartis Emergency Management team (2010), and Bio-safety Officer (2011)

Other achievements

• Secured external funding to support research programs within various consortia:

o Development of predictive animal models of TB infection, BMGF Accelerator Program (2008-2009 with Pasteur-Brussels and PHRI, NJ)

o Imaging of drug distribution into tuberculous lesions of animal models, BMGF Accelerator Program (2008-2010 with University Pittsburgh, NIH-NIAID, Scripps Research Institute and Oxford University)

o Human studies of drug penetration into pulmonary TB lesions, BMGF GCGH11 Program (2005-2011 with Imperial College London, NIH/NIAID, Cornell Medical College and Asan/Samsung Medical Centre in Korea)

o Novel MassArray methodology for high throughput detection of TB drug resistance in Africa, UBS Optimus Foundation (2009-2011 with Swiss Tropical Institute)

• Provided pharmacology support for clinical research trials and multicenter studies in South Korea in collaboration with NIH-NIAID (NIH protocols #07-I-N041; #08-I-N167, and #09-I-N061)

2004 Senior Scientist, Adaptive Therapeutics Inc., San Diego, CA

• Head of in vivo biology group

• Coordinated and executed PK/PD studies in animal models for the study of in vivo effects of discovery-stage antimicrobial agents

o Acute toxicology studies

o Pharmacokinetic evaluation

o Efficacy evaluation, multiple infection models

1997-2003 Principal Scientist, Embiosis Pharmaceuticals, Inc., Carlsbad, CA.

• Developed and optimized proprietary techniques and host vector systems for extracting, cloning and expressing DNA from environmental microbes

• Developed metabolic selection strategies (US Patent 6,368,793) for the identification of new enzymes and microbial pathways from unculturable bacterial species for the production of chemicals and pharmaceutical compounds

• Central in establishing and expanding the Company intellectual property portfolio: strategy, application drafts, responses to office actions in conjunction with patent attorneys

• Developed and implemented screening strategies to uncover novel pathways from environmental microbes for the production of small bioactive molecules

• Participated in regular meetings with business partners and fund raising events

1996-1997 Postdoctoral Fellow, Dept. of Microbial Biochemistry, Pasteur Institute, Paris.

Signal transduction networks that control cellular differentiation and degradative enzyme production in Bacillus subtilis.

1993-1996 Postdoctoral Fellow, Division of Cell Biology, Scripps Research Institute, La Jolla, CA. Characterization of pathways involved in activation of the Bacillus subtilis sporulation phosphorelay.

Adjunct and steering committee positions

• Member of the Research Steering Group of the University of Dundee since 2013

• Member of the CPTR working group on Biomarkers of Clinical Endpoints since 2013

• Member of the Scientific Steering Committee of the International Tuberculosis Research Center in Masan, South Korea, since 2008.

AWARDS AND INVITED LECTURES

Awards

• NIBR Team Award for the discovery and development of malaria clinical candidate NITD609

• Co-chair of the Gordon Research Conference 2013 on TB Drug Development

• Associate Editor of the International Journal of Antimicrobial Agents 2014-2016

Recent Invited Lectures

• Keystone Symposium on “Tuberculosis, Understanding the Enemy”, Whistler, 2013

• The 9th International conference on the Pathogenesis of Mycobacterial Infections, June 26-29 2014, Stockholm, Sweden

• H-3D Symposium on “Innovative Approaches to TB Drug Discovery”, Zambia, 2014

• Gordon Research Conference and Gordon Research Seminar on “TB Drug Development”, Girona, July 2015

• ICAAC on “Lung and tubercular drug exposure”, San Diego, September 2015

• Inauguration of the Francis Crick Institute, “Penetration of TB drugs in pulmonary lesions” London, March 2016

• Experimental Biology (ASBMB section) on “MALDI Mass Spectrometry Imaging: the Pyrazinamide Enigma”, San Diego, April 2016

• ASM Microbe, Boston, June 2016

• Keystone Symposium on “New Developments in Our Basic Understanding of Tuberculosis (A5), Vancouver, Jan 14-18, 2017

• ASM Microbe 2017, June 1-5, New Orleans

• 10th workshop on the Clinical Pharmacology of TB Drugs, Atlanta, Oct 15, 2017

• Keystone Symposium on “Tuberculosis: Translating Scientific Findings for Clinical and Public Health Impact”, Whistler, April 15 - 19, 2018

• ASM Microbe 2018, Atlanta, June 7-11, 2018

EDUCATION

1992 Ph. D., Microbiology, Dept. of Microbial Genetics, Université Catholique de Louvain, Belgium. Thesis: Genetics of lipolytic activity in Bacillus subtilis.

1986 B. S., Biology, Université Catholique de Louvain, Belgium. Undergraduate study: Characterization of an endoglucanase gene from Pseudomonas fluorescens

PUBLICATIONS

1. Lejeune A., V. Dartois and C. Colson. 1988. Characterization and expression in Escherichia coli of an endoglucanase gene of Pseudomonas fluorescens subsp. cellulosa. Biochim. Biophys. Acta 950:204-214.

2. Dartois V., A. Baulard, K. Schank and C. Colson. 1991. Cloning, sequencing and expression in Escherichia coli of a lipase gene from Bacillus subtilis 168. Biochim. Biophys. Acta 1131:253-260.

3. Colson C., V. Dartois, K. Schanck and A. Baulard. 1991. The lipase gene of Bacillus subtilis 168. In Lipases: structure, mechanism and genetic engineering. L. Alberghina, R.D. Schmid and R. Verger, eds., GBF Monographs, vol. 16, pp 277-283.

4. Dartois V., O. De Backer and C. Colson. 1993. Sequence of the Salmonella typhimurium StyLT1 restriction-modification genes: homologies with EcoP1 and EcoP15 type III R-M systems and presence of helicase domains. Gene 127:105-110.

5. Baulard A., P.Bertin, V. Dartois and C. Locht. 1993. Reincarnation of plasmids from dead bacteria by electroduction. Meth. Mol. Cell. Biol. 4:177-179.

6. Dartois V., J-Y. Coppée, C. Colson and A.Baulard. 1994 Genetic analysis and overexpression of lipolytic activity in Bacillus subtilis. Appl. Environ. Microbiol. 60:1670-1673.

7. Misset O., G. Gerritse, K. E. Jaeger, U. Winkler, C. Colson, K. Schanck., E.Lesuisse, V.Dartois, M. Blaauw, S.Ransae et al. 1994. The structure-function relationship of the lipases from Pseudomonas aeruginosa and Bacillus subtilis. Protein Eng. 7:523-529.

8. Phalip V., V. Dartois, P. Schmitt and C. Diviès. 1994. Cloning of the D-lactate dehydrogenase gene from Leuconostoc mesenteroides subsp. cremoris. Biotechnol. Lett. 16:221-226.

9. Dartois V., V. Phalip, P. Schmitt, and C. Diviès. 1995. Purification, properties and DNA sequence of the D-lactate dehydrogenase from Leuconostoc mesenteroides subsp. cremoris. Res. Microbiol. 146:291-302.

10. Dartois V., T. Djavakhishvili and J. A. Hoch. 1996. Identification of a membrane protein involved in activation of the KinB pathway to sporulation in Bacillus subtilis. J. Bacteriol. 178:1178-1186.

11. Dartois V., J. Liu and J. A. Hoch. 1997. Alterations in the flow of one-carbon units affect KinB-dependent sporulation in Bacillus subtilis. Mol. Microbiol. 25:39-51.

12. Dartois V., T. Djavakhishvili and J. A. Hoch. 1997. KapB is a lipoprotein required for KinB signal transduction and activation of the phosphorelay to sporulation in Bacillus subtilis. Mol. Microbiol. 26:1097-1108.

13. Cavin, J.-F., V. Dartois and C. Divies. 1998. Gene cloning, transcriptional analysis, purification and characterization of phenolic acid decarboxylase from Bacillus subtilis. Appl. Environ. Microbiol. 64:1466-1471.

14. Msadek T., V. Dartois, F. Kunst, M-L. Herbaud, F. Denizot and G. Rapoport. 1998. ClpP of Bacillus subtilis is required for competence development, motility, degradative enzyme synthesis, growth at high temperature and sporulation. Mol. Microbiol. 27:899-914.

15. Dartois V., M. Débarbouillé, F. Kunst and G. Rapoport. 1998. Characterization of a novel member of the DegS/DegU regulon affected by salt stress in Bacillus subtilis. J. Bacteriol, 180:1855-1861.

16. Bandell M., M.E. Lhotte, C. Marty-Teysset, A. Veyrat, H. Prevost, V. Dartois, C. Divies, W. N. Konings, J. S. Lolkema. 1998. Mechanism of the citrate transporters in carbohydrate and citrate cometabolism in Lactococcus and Leuconostoc species. Appl. Environ. Microbiol. 64:1594-600.

17. Cavin J.F., V. Dartois, C. Labarre and C. Divies. 1999. Cloning of branched chain amino acid biosynthesis genes and assays of alpha-acetolactate synthase activities in Leuconostoc mesenteroides subsp. cremoris. Res. Microbiol. 150:189-198.

18. Wang, L., Fabret, C., Kanamura, K., Stephenson, K., Dartois, V., Perego, M., and J. A. Hoch. 2001. Dissection of the functional and structural domains of phosphorelay histidine kinase A of Bacillus subtilis. J. Bacteriol. 183:2795-2802.

19. Dartois, V., Sanchez-Quesada, J., Cabezas, E., Chi, E., Dubbelde, C., Dunn C., Granja, J., Gritzen, C., Weinberger, D., Ghadiri, M. R., and TR Parr Jr. 2005. Systemic antibacterial activity of novel synthetic cyclic peptides. Antimicrob. Agents Chemother. 49:3302-3310.

20. Teo JW, Thayalan P, Beer D, Yap AS, Nanjundappa M, Ngew X, Duraiswamy J, Liung S, Dartois V, Schreiber M, Hasan S, Cynamon M, Ryder NS, Yang X, Weidmann B, Bracken K, Dick T, Mukherjee K. 2006. Peptide deformylase inhibitors as potent antimycobacterial agents. Antimicrob. Agents Chemother. 50:3665-3673.

21. Tran NP, Gury J, Dartois V, Nguyen TK, Seraut H, Barthelmebs L, Gervais P, Cavin JF. 2008. Phenolic acid-mediated regulation of the padC gene, encoding the phenolic acid decarboxylase of Bacillus subtilis. J Bacteriol. 190:3213-3224.

22. Dick T., Dartois V., Keller T. and Matter A. 2007. TB drug discovery from target identification to proof of concept studies; p139-159, Handbook of Tuberculosis; Clinics, Diagnostics, Therapy and Epidemiology. Eds S.H.E. Kaufmann and P. van Helden. Wiley-VCH, Weinheim

23. Kurabachew M, Lu SH, Krastel P, Schmitt EK, Suresh BL, Goh A, Knox JE, Ma NL, Jiricek J, Beer D, Cynamon M, Petersen F, Dartois V, Keller T, Dick T, Sambandamurthy VK. 2008. Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis. J Antimicrob Chemother. 62:713-719.

24. Dartois V, Leong FJ, Dick T. 2008. TB drug discovery: issues, gaps and the way forward. In Drug Discovery in Infectious Diseases, Seltzer P. Ed, Wiley-VCH, Weinheim, pp 415-440.

25. Barry CE 3rd, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ, Young D. 2009. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 7:845-855.

26. Yin Z, Chen YL, Schul W, Wang QY, Gu F, Duraiswamy J, Kondreddi RR, Niyomrattanakit P, Lakshminarayana SB, Goh A, Xu HY, Liu W, Liu B, Lim JY, Ng CY, Qing M, Lim CC, Yip A, Wang G, Chan WL, Tan HP, Lin K, Zhang B, Zou G, Bernard KA, Garrett C, Beltz K, Dong M, Weaver M, He H, Pichota A, Dartois V, Keller TH, Shi PY. 2009. An adenosine nucleoside inhibitor of dengue virus. Proc Natl Acad Sci U S A. 106:20435-20439.

27. Nzila A, Rottmann M, Chitnumsub P, Kiara SM, Kamchonwongpaisan S, Maneeruttanarungroj C, Taweechai S, Yeung BK, Goh A, Lakshminarayana SB, Zou B, Wong J, Ma NL, Weaver M, Keller TH, Dartois V, Wittlin S, Brun R, Yuthavong Y, Diagana TT. 2010 Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate. Antimicrob Agents Chemother. 54:2603-2610

28. Chen YL, Yin Z, Lakshminarayana SB, Qing M, Schul W, Duraiswamy J, Kondreddi RR, Goh A, Xu HY, Yip A, Liu B, Weaver M, Dartois V, Keller TH, Shi PY. 2010. Inhibition of Dengue Virus by an Ester Prodrug of an Adenosine Analog. 2010. Antimicrob Agents Chemother. 54:3255-3261

29. Yeung BK, Zou B, Rottmann M, Lakshminarayana SB, Ang SH, Leong SY, Tan J, Wong J, Keller-Maerki S, Fischli C, Goh A, Schmitt EK, Krastel P, Francotte E, Kuhen K, Plouffe D, Henson K, Wagner T, Winzeler EA, Petersen F, Brun R, Dartois V, Diagana TT, Keller TH. 2010. Tetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria. J Med Chem. 53:5155-5164

30. Rottmann M, McNamara C, Yeung BKS, Lee MCS, Bin Zou, Russell B, Seitz P, Plouffe DM, Dharia NV, Tan J, Cohen SB, Spencer KR, González-Páez GE, Lakshminarayana SB, Goh A, Suwanarusk R, Jegla T, Schmitt EK, Beck H-P, Brun R, Nosten F, Renia L, Dartois V, Keller TH, Fidock D, Winzeler E, and Diagana TT. 2010. Spiroindolones, a new and potent chemotype for the treatment of malaria. Science, 329:1175-80.

31. Pethe K, Sequeira PC, Agarwalla S, Rhee K, Kuhen K, Phong WY, Patel V, Beer D, Walker JR, Duraiswamy J, Jiricek J, Keller TH, Chatterjee A, Tan MP, Ujjini M, Rao SP, Camacho L, Bifani P, Mak PA, Ma I, Barnes SW, Chen Z, Plouffe D, Thayalan P, Ng SH, Au M, Lee BH, Tan BH, Ravindran S, Nanjundappa M, Lin X, Goh A, Lakshminarayana SB, Shoen C, Cynamon M, Kreiswirth B, Dartois V, Peters EC, Glynne R, Brenner S, Dick T. 2010. A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source dependent growth inhibitors deprived of in vivo efficacy. Nat. Comm. 1:1-8

32. A Color Atlas of Comparative Pathology of Pulmonary Tuberculosis. F J Leong, V Dartois, and T Dick, Eds, CRC Press 2010.

33. Prideaux B, Dartois V, Staab D, Weiner DM, Goh A, Via LE, Barry Iii CE, Stoeckli M. 2011. High-Sensitivity MALDI-MRM-MS Imaging of Moxifloxacin Distribution in Tuberculosis-Infected Rabbit Lungs and Granulomatous Lesions. Anal Chem. 83(6):2112-2118

34. Singhal A, Aliouat el M, Hervé M, Mathys V, Kiass M, Creusy C, Delaire B, Tsenova L, Fleurisse L, Bertout J, Camacho L, Foo D, Tay HC, Siew JY, Boukhouchi W, Romano M, Mathema B, Dartois V, Kaplan G, Bifani P. 2011. Experimental tuberculosis in the wistar rat: a model for protective immunity and control of infection. PLoS One. 6(4):e18632

35. Foo DG, HC Tay, JY Siew, A Singhal, L Camacho, P Bifani, V Dartois, and M Hervé. 2011. T cell monitoring of chemotherapy in experimental rat tuberculosis. Antimicrob Agents Chemother 55:3677-3683.

36. Heng Y, Seah PG, Siew JY, Tay HC, Singhal A, Mathys V, Kiass M, Bifani P, Dartois V, Hervé M. 2011. Mycobacterium tuberculosis infection induces hypoxic lung lesions in the rat. Tuberculosis 91:339-341.

37. Wu T, Nagle A, Kuhen K., ..., Rottmann M, Dartois V, Keller T, Diagana T, Winzeler E, Glynne R, Tully DC, Chatterjee AK. 2011. Imidazolopiperazines: Hit to Lead Optimization of New Antimalarial Agents. J Med Chem. 54:5116-5130.

38. Cherian J, Choi I, Nayyar A, Manjunatha UH..., Dick T, Keller TH, Dartois V, and Barry CE III. 2011. Structure-Activity Relationships of Antitubercular Nitroimidazoles. 3. Exploration of the Linker and Lipophilic Tail of ((S)-2-Nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxy-benzyl)amine (6-Amino PA-824). J Med Chem. 54:5639-5659

39. Manier ML, ML Reyzer, A Goh, V Dartois, LE Via, CE Barry III, RM Caprioli. 2011. Reagent Precoated Targets for Rapid In-Tissue Derivatization of the Anti-Tuberculosis Drug Isoniazid Followed by MALDI Imaging Mass Spectrometry. J. Am. Soc. Mass Spectrom, 22(8):1409-1419

40. Kjellsson MC, Via LE, Goh A, Weiner D, Low KM, Kern S, Pillai G, Barry CE III and V Dartois. 2012. Penetration of anti-tuberculosis agents in rabbit pulmonary lesions: a pharmacokinetic evaluation. Antimicrob Agents Chemother, 56(1):446-457

41. Dartois V. 2011. Drug forgiveness and inter-patient pharmacokinetic variability in Tuberculosis. J Infect Dis, 204(12):1827-1829

42. Subbian S, Tsenova L, O'Brien P, Yang G, Koo M-S, Peixoto B, Fallows B, Dartois V, Muller G, and G Kaplan. 2011. Phosphodiesterase-4 Inhibition Alters Gene Expression and Improves Isoniazid – Mediated Clearance of Mycobacterium tuberculosis in Rabbit Lungs. PLoS Pathog, 7(9):e1002262

43. Shui G, Bendt AK, Jappar IA, Lim HM, Laneelle M, Hervé M, Via LE, Chua GH, Bratschi MW, Hwang S-H, Lee JS, Eum SY, Kwak HK, Daffé M, Dartois V, Michel G, Barry CE III and MR Wenk. 2012. Mycolic acids as diagnostic markers for tuberculosis case detection in humans and drug efficacy in mice. EMBO Mol Med, 4(1):27-37

44. Singhal A, Mathys V, Kiass M, Creusy C, Delaire B, Aliouat El M, Dartois V, Kaplan G, Bifani P. 2011. BCG induces protection against Mycobacterium tuberculosis infection in the Wistar rat model. PLoS One. 6(12):e28082

45. Via LE, Schimel D, Weiner DM, Dartois V, Dayao E, Cai Y, Yoon YS, Dreher MR, Kastenmayer RJ, Laymon CM, Carny JE, Flynn JL, Herscovitch P, Barry CE 3rd. 2012. Infection Dynamics and Response to Chemotherapy in a Rabbit Model of Tuberculosis using [18F]2-Fluoro-Deoxy-D-Glucose Positron Emission Tomography and Computed Tomography. Antimicrob Agents Chemother. 56(8):4391-402

46. Lin PL, Dartois V, Johnston PJ, Janssen C, Via L, Goodwin MB, Klein E, Barry CE 3rd, Flynn JL. 2012. Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proc Natl Acad Sci U S A., 109(35):14188-93

47. Franzblau SG, DeGroote MA, Cho SH, Andries K, Nuermberger E, Orme IM, Mdluli K, Angulo-Barturen I, Dick T, Dartois V, and AJ Lenaerts. 2012. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis, 92(6):453-88

48. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, Via LE, Goldfeder LC, Kang E, Jin B, Park H, Kwak H, Kim H, Jeon HS, Jeong I, Joh JS, Chen RY, Olivier KN, Shaw PA, Follmann D, Song SD, Lee JK, Lee D, Kim CT, Dartois V, Park SK, Cho SN, and Clifton E. Barry III. 2012. Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis. New Engl J Med., 367(16):1508-1518

49. Sarathy J, Dartois V, Lee EJD. 2012. The Role of Transport Mechanisms in Mycobacterium Tuberculosis Drug Resistance and Tolerance. Pharmaceuticals, 5(11):1210-1235.

50. Sarathy J, Dartois V, Dick T and M. Gengenbacher. 2013. Reduced drug uptake in phenotypically resistant nutrient-starved non-replicating Mycobacterium tuberculosis. Antimicrob Agents Chemother, 57(4):1648-53 (PMID: 23335744)

51. Carroll MW, Jeon D, Mountz JM, Lee JD, Jeong YJ, Zia N, Lee M, Lee J, Via LE, Lee S, Eum SY, Lee SJ, Goldfeder LC, Cai Y, Jin B, Kim Y, Oh T, Chen RY, Dodd LE, Gu W, Dartois V, Park SK, Kim CT, Barry CE 3rd, Cho SN. 2013. Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 57(8):3903-9

52. Sarathy JP, Lee E, Dartois V. 2013. Polyamines inhibit porin-mediated fluoroquinolone uptake in mycobacteria. PLoS One. 8(6):e65806

53. Lin PL, Coleman T, Carney JP, Lopresti BJ, Tomko J, Fillmore D, Dartois V, Scanga C, Frye LJ, Janssen C, Klein E, Barry CE 3rd, Flynn JL. 2013. Radiologic responses in cynomolgous macaques for assessing tuberculosis chemotherapy regimens. Antimicrob Agents Chemother. 57:9 4237-4244

54. Dartois V, Barry CE 3rd. 2013. A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis. Bioorg Med Chem Lett. 23(17):4741-50 (PMID: 23910985)

55. Rao SP, Lakshminarayana SB, Kondreddi RR, Herve M, Camacho LR, Bifani P, Kalapala SK, Jiricek J, Ma NL, Tan BH, Ng SH, Nanjundappa M, Ravindran S, Seah PG, Thayalan P, Lim SH, Lee BH, Goh A, Barnes WS, Chen Z, Gagaring K, Chatterjee AK, Pethe K, Kuhen K, Walker J, Feng G, Babu S, Zhang L, Blasco F, Beer D, Weaver M, Dartois V, Glynne R, Dick T, Smith PW, Diagana TT, Manjunatha UH. 2013. Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis. Sci Transl Med. 5(214): 1-10.

56. Y J Zhang, M C Reddy, T R Ioerger, A C Rothchild, V Dartois, B M Schuster, A Trauner, S Valluru, C Huttenhower, J C Sacchettini, S M Behar, E J Rubin. 2013. Interfering with mycobacterial metabolism synergizes with immune-mediated killing. Cell 155(6):1296-308

57. Dartois V. Anti-tuberculosis drug dynamics: from blood to lesions to single cells. 2014. Nat Rev Microbiol. 12(3):159-67

58. Prideaux B., ElNaggar MS, Zimmerman M., Wiseman JM, Li X and Dartois V. 2014. Mass spectrometry imaging of levofloxacin distribution in TB-infected pulmonary lesions by MALDI-MSI and continuous liquid microjunction surface sampling. Int J Mass Spectrom., 377:699-708.

59. Coleman MT, Chen RY, Lee M, Philana L Lin, Dodd LE, Maiello P, Via LE, Kim Y, Marriner G, Dartois V, Scanga C, Janssen C, Jing Wang, Klein E, Sang Nae Cho, Barry CE III, and JL Flynn. 2014. PET/CT monitoring demonstrates a therapeutic response to oxazolidinones in Mycobacterium tuberculosis infected macaques and humans. Sci Transl Med, 6(265):265ra167

60. Lakshminarayana S., Tan B., Ho P., Manjunatha U., Dartois V.*, Dick T., Rao, S. 2014. Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-tuberculosis agents. J Antimicrob Chemother, 70(3):857-67

61. Lenaerts A., Barry CE III and V Dartois. 2015. Heterogeneity in Tuberculosis Pathology, Microenvironments and Therapeutic Responses. Immunological Reviews, 264(1):288-307

62. Pienaar E, Cilfone N, Philana L Lin; Dartois V, Mattila JT, Butler R, Flynn JL, Kirschner D and JJ Linderman. 2015. A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment. J Theor Biol, 367: 166–179

63. Lakshminarayana SB, Freymond C, Fischli C, Yu J, Weber S, Goh A, Yeung BK, Ho PC, Dartois V, Diagana TT, Rottmann M, Blasco F. 2015. Pharmacokinetics-pharmacodynamics analysis of spiroindolone analogs and KAE609 in a murine malaria model. Antimicrob Agents Chemother., 59(2):1200-10

64. Via LE, Savic R, Weiner DM, Zimmerman MD, Prideaux B, Irwin SM, Lyon E, O’Brien P, Goopal P, Eum S, Lee M, Lanoix J-P, Dutta NK, Shim TS, Cho JS, Kim W, Karakousis PC, Lenaerts A, Nuermberger E, Barry CE III and V Dartois*. 2015. Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives. ACS Infectious Diseases, 1:203-214

65. Via, LE, England K, Weiner D, Schimel D, Zimmerman MD, Dayao E, Chen R, Dodd L, Richardson M, Robbins K, Cai Y, Hammoud D, Herscovitch P, Dartois V, Flynn J and CE Barry. 2015. A sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosets. Antimicrob Agents Chemother., 59(7):4181-9.

66. DeMarco VP, Ordonez AA, Klunk M, Prideaux B, Wang H, Zhuo Z, Tonge PJ, Dannals RF, Holt DP, Lee CK, Weinstein EA, Dartois V, Dooley KE, Jain SK. 2015. Determination of 11C-Rifampin Pharmacokinetics within Mycobacterium tuberculosis-Infected Mice Using Dynamic Positron Emission Tomography Bioimaging. Antimicrob Agents Chemother., 59(9):5768-74

67. Prideaux B, Via LE, Zimmerman MD, Eum S, Sarathy J, O'Brien P, Chen C, Kaya F, Weiner DM, Chen PY, Song T, Lee M, Shim TS, Cho JS, Kim W, Cho SN, Olivier KN, Barry CE 3rd, Dartois V. 2015. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat Med. 21(10):1223-7.

68. Tasneen R, Betoudji F, Tyagi S, Li SY, Williams K, Converse PJ, Dartois V, Yang T, Mendel CM, Mdluli KE, Nuermberger EL. 2015. Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis. Antimicrob Agents Chemother., 60(1):270-7.

69. Lanoix JP, Ioerger T, Ormond A, Kaya F, Sacchettini J, Dartois V, Nuermberger E. 2015. Selective inactivity of pyrazinamide against tuberculosis in C3HeB/FeJ mice is best explained by neutral pH of caseum. Antimicrob Agents Chemother. 16;60(2):735-43.

70. Pienaar E, Dartois V, Linderman JJ, Kirschner DE. 2015. In silico evaluation and exploration of antibiotic tuberculosis treatment regimens. BMC Syst Biol. Nov 14; 9:79.

71. Lee SJ, Desta KT, Eum SY, Dartois V, Cho SN, Bae DW, Shin SC. 2016. Development and validation of LC-ESI-MS/MS method for analysis of moxifloxacin and levofloxacin in serum of multidrug-resistant tuberculosis patients: Potential application as therapeutic drug monitoring tool in medical diagnosis. J Chromatogr B Analyt Technol Biomed Life Sci., 2(11):1627-33

72. Subbian S, Tsenova L, Holloway J, Peixoto B, O'Brien P, Dartois V, Khetani V, Zeldis JB, Kaplan G. 2016. Adjunctive Phosphodiesterase-4 Inhibitor Therapy Improves Antibiotic Response to Pulmonary Tuberculosis in a Rabbit Model. EBioMedicine. 4:104-14

73. Marakalala MJ, Raju RM, Sharma K, Zhang YJ, Eugenin EA, Prideaux B, Daudelin IB, Chen PY, Booty MG, Kim JH, Eum SY, Via LE, Behar SM, Barry CE 3rd, Mann M, Dartois V, Rubin EJ. 2016. Inflammatory signaling in human tuberculosis granulomas is spatially organized. Nat. Med., 22(5):531-8

74. Liu Y, Tan S, Huang L, Abramovitch RB, Rohde KH, Zimmerman MD, Chen C, Dartois V, VanderVen BC, Russell DG. 2016. Immune activation of the host cell induces drug tolerance in Mycobacterium tuberculosis both in vitro and in vivo. J Exp Med. 213(5):809-25

75. Irwin, S. M., B. Prideaux, E. R. Lyon, M. D. Zimmerman, E. J. Brooks, C. A. Schrupp, C. Chao, M. J. Reichlen, B. C. Asay, M. I. Voskuil, E. L. Nuermberger, K. Andries, M. A. Lyons, V. Dartois and A. J. Lenaerts. 2016. Bedaquiline and Pyrazinamide Treatment Responses are Affected by the Heterogeneity in Pulmonary Lesions in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice. ACS Infect. Dis., 2016. 2(4): p. 251-267.

76. Lanoix, J-P., Tasneen, R., O’Brien, P., Sarathy, J., Safi, H., Pinn, M., Alland, D. A., Dartois, V. and E. Nuermberger. 2016. High systemic exposure of pyrazinoic acid has limited anti-tuberculosis activity in murine and rabbit models of tuberculosis. Antimicrob Agents Chemother., 60(7):4197-205

77. Gold, B., Smith, R., Nguyen, Q., Roberts, J., Ling Y, Lopez Quezeda L, Somersan-Karakaya S, Warrier T, Little D, Pingle M, Zhang D, Ballinger E, Zimmerman M, Dartois V, Hanson PR, Mitscher LA, Porubsky P, Rogers S, Schoenen FJ, Nathan CF, Aubé J. 2016. Novel cephalosporins selectively active on non-replicating Mycobacterium tuberculosis. J. Med. Chem., 59(13):6027-44

78. Jansy P. Sarathy, Fabio Zuccotto, Ho Hsinpin, Lars Sandberg, Laura E. Via, Gwendolyn A. Marriner, Thierry Masquelin, Paul Wyatt, Peter Ray, and V. Dartois. 2016. Prediction of Drug Penetration in Tuberculosis Lesions. ACS Infect. Dis., 2 (8), pp 552–563

79. Park Y, Pacitto A, Bayliss T, Cleghorn LA, Wang Z, Hartman T, Arora K, Ioerger TR, Sacchettini J, Rizzi M, Donini S, Blundell TL, Ascher DB, Rhee KY, Breda A, Zhou N, Dartois V, Jonnala SR, Via LE, Mizrahi V, Epemolu O, Stojanovski L, Simeons FR, Osuna-Cabello M, Ellis L, MacKenzie CJ, Smith AR, Davis SH, Murugesan D, Buchanan KI, Turner PA, Huggett M, Zuccotto F, Rebollo-Lopez MJ, Lafuente-Monasterio MJ, Sanz O, Santos Diaz G, Lelièvre J, Ballell L, Selenski C, Axtman M, Ghidelli-Disse S, Pflaumer H, Boesche M, Drewes G, Freiberg G, Kurnick MD, Srikumaran M, Kempf DJ, Green SR, Ray PC, Read KD, Wyatt PG, Barry Rd CE, Boshoff HI. 2016. Essential but not vulnerable: indazole sulfonamides targeting inosine monophosphate dehydrogenase as potential leads against Mycobacterium tuberculosis. ACS Infect Dis. 3(1):18-33

80. Dutta NK, Bruiners N, Pinn ML, Zimmerman MD, Prideaux P, Dartois V, Gennaro ML, Karakousis P. 2016. Statin adjunctive therapy shortens TB treatment in mice. J Antimicrob Chemother. 2016 Jun;71(6):1570-7

81. Gopal P, Yee M, Sarathy J, Low JL, Sarathy JP, Kaya F, Dartois V, Gengenbacher M, Dick T. 2016. Pyrazinamide Resistance Is Caused by Two Distinct Mechanisms: Prevention of Coenzyme A Depletion and Loss of Virulence Factor Synthesis. ACS Infect Dis. 2(9):616-626

82. Dartois V, Saito K, Warrier T, Nathan C. 2016. New Evidence for the Complexity of the Population Structure of Mycobacterium tuberculosis Increases the Diagnostic and Biologic Challenges. Am J Respir Crit Care Med. 194(12):1448-1451

83. Gopal P, Tasneen R, Yee M, Lanoix JP, Sarathy J, Rasic G, Li L, Dartois V, Nuermberger E, Dick T. 2017. In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1. ACS Infect Dis., 3(7):492-501

84. Aziz DB, Low JL, Wu ML, Gengenbacher M, Teo JW, Dartois V, Dick T. 2017. Rifabutin Is Active Against Mycobacterium abscessus Complex. Antimicrob Agents Chemother., in press

85. Mishra BB, Lovewell RR, Olive AJ, Zhang G, Wang W, Eugenin E, Smith CM, Phuah JY, Long JE, Dubuke ML, Palace SG, Goguen JD, Baker RE, Nambi S, Mishra R, Booty MG, Baer CE, Shaffer SA, Dartois V, McCormick BA, Chen X, Sassetti CM. 2017. Nitric oxide prevents a pathogen-permissive granulocytic inflammation during tuberculosis. Nat Microbiol, May 15;2:17072

86. Sarathy JP, Liang HH, Weiner D, Gonzales J, Via LE, Dartois V. 2017 An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions. J Vis Exp. 2017 May 8;(123).

87. Zimmerman M, Lestner J, Prideaux B, O'Brien P, Freedman I, Chen C, Dietzold J, Daudelin I, Kaya F, Blanc L, Chen PY, Park S, Salgame P, Sarathy J, Dartois V. 2017. Ethambutol partitioning in tuberculous pulmonary lesions explains its clinical efficacy. Antimicrob Agents Chemother, in press

88. Naftalin CM, Verma R, Gurumurthy M, Lu Q, Zimmerman M, Yeo BCM, Tan KH, Lin W, Yu B, Dartois V, Paton NI. 2017. Co-administration of allopurinol to increase anti-mycobacterial efficacy of pyrazinamide: evaluation in a whole-blood bactericidal activity model. Antimicrob Agents Chemother, in press

89. Zhao Y, Prideaux B, Nagasaki Y, Lee MH, Chen PY, Blanc L, Ho H, Clancy CJ, Nguyen MH, Dartois V, Perlin DS. 2017. Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-Abdominal Abscess Model. Antimicrob Agents Chemother, in press

90. Pienaar E, Sarathy J, Prideaux B, Dietzold J, Dartois V, Kirschner DE, Linderman JJ. 2017. Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach. PLoS Comput Biol., in press

91. Gengenbacher M, Duque-Correa MA, Kaiser P, Schuerer S, Lazar D, Zedler U, Reece ST, Nayyar A, Cole ST, Makarov V, Barry CE III, Dartois V, Kaufmann SHE. 2017. NOS2-deficient mice with hypoxic necrotizing lung lesions predict outcomes of tuberculosis chemotherapy in humans. Sci Rep. 18;7(1):8853

92. Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L. 2017. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Breast Cancer Res. 19(1):10

93. Gopal P, Nartey W, Ragunathan P, Sarathy JP, Kaya F, Yee M, Setzer C, Manimekalai MSS, Dartois V, Grüber G, Dick T. 2017. Pyrazinoic acid inhibits mycobacterial coenzyme A biosynthesis by binding to aspartate decarboxylase PanD. ACS Infect Dis, in press

94. Sarathy JP, Via LE, Weiner D, Blanc L, Boshoff H, Eugenin EA, Barry CE 3rd, Dartois VA. Extreme drug tolerance of Mycobacterium tuberculosis in caseum. 2017. Antimicrob Agents Chemother, in press

95. Negatu DA, Liu JJJ, Zimmerman M, Kaya F, Dartois V, Aldrich CC, Gengenbacher M, Dick T. Whole cell screen of fragment library identifies gut microbiota metabolite indole propionic acid as antitubercular. 2017. Antimicrob Agents Chemother, in press

96. Inoyama D, Paget SD, Russo R, Kandasamy S, Kumar P, Singleton E, Occi J, Tuckman M, Zimmerman MD, Ho HP, Perryman AL, Connell N, Freundlich JS. 2018. Novel Pyrimidines as Antitubercular Agents. Antimicrob Agents Chemother. 62(3)

97. Chen C, Gardete S, Jansen RS, Shetty A, Dick T, Rhee KY, Dartois V. 2018. Verapamil Targets Membrane Energetics in Mycobacterium tuberculosis. Antimicrob Agents Chemother. Apr 26;62(5).

98. Millard J, Pertinez H, Bonnett L, Hodel EM, Dartois V, Johnson JL, Caws M, Tiberi S, Bolhuis M, Alffenaar JC, Davies G, Sloan DJ. 2018. Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation. J Antimicrob Chemother. In press

99. Rifat D, Prideaux B, Savic RM, Urbanowski ME, Parsons TL, Luna B, Marzinke MA, Ordonez AA, DeMarco VP, Jain SK, Dartois V, Bishai WR, Dooley KE. 2018. Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data. Sci Transl Med. Apr 4;10(435).

100. Wu ML, Aziz DB, Dartois V, Dick T. 2018. NTM drug discovery: status, gaps and the way forward. Drug Discov Today, in press.

101. Blanc L, Lenaerts A, Dartois V, Prideaux B. 2018. Visualization of Mycobacterial Biomarkers and Tuberculosis Drugs in Infected Tissue by MALDI-MS Imaging. Anal Chem., in press

102. Tiwari D, Park SW, Essawy MM, Dawadi S, Mason A, Nandakumar M, Zimmerman M, Mina M, Ho HP, Engelhart CA, Ioerger T, Sacchettini JC, Rhee K, Ehrt S, Aldrich CC, Dartois V, Schnappinger D. 2018. Targeting protein biotinylation enhances tuberculosis chemotherapy. Sci Transl Med. Apr 25;10(438)

103. Xu Y, Wang L, Zimmerman MD, Chen KY, Huang L, Fu DJ, Kaya F, Rakhilin N, Nazarova EV, Bu P, Dartois V, Russell DG, Shen X. 2018. Matrix metalloproteinase inhibitors enhance the efficacy of frontline drugs against Mycobacterium tuberculosis. PLoS Pathog. Apr 26;14(4)

PATENTS

1. Hoch, J. A. and V. Dartois. Metabolic Selection Strategy. U.S. Patent No. 6,368,793. Issued April 9, 2002.

2. Dartois V. and J. A. Hoch. 2,5-DKG permeases. U.S. Patent No. 6,720,168 B2. Issued Apr 13, 2004.

PERSONAL

Date of birth: November 29, 1964

Citizenship: Belgium, US permanent resident since December 2000

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download